Physician profile
Richard Lang
NPI 1699347096
$1,626.99
in general payments reported to CMS, 2019-2025
10 companies · $567 in 2025
The $567 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.72 · 2022: $248 · 2023: $448 · 2024: $298 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $453.14 | 2021-2025 | Rocklatan, Voyager Dslt, Total30 |
| Coopervision INC. | $451.02 | 2022-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $404.05 | 2023-2025 | Miebo, Infuse Multifocal, Xiidra |
| Oyster Point Pharma, INC. | $125.00 | 2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.61 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $43.69 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $36.34 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $32.09 | 2022-2025 | |
| Lkc Technologies, INC. | $18.55 | 2025 | |
| Harrow Eye, LLC | $15.50 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.